Christopher Reeg - Fuse Medical CEO, Director

All Insiders . USA . 
Stock . Fuse Medical . Stakeholders . Insider . Christopher Reeg
FZMD Stock  USD 0.12  0.07  140.00%   

CEO

Mr. Christopher C. Reeg is Chief Executive Officer, Secretary, Director of the Company. Our Board appointed Mr. Reeg to the additional role of Secretary. Mr. Reeg has also served as the Chief Executive Officer of CPM since 2017 and Maxim since 2018. Mr. Reeg founded Maxim in 2011 and served as its President until we acquired Maxim in August 2018 since 2018.
Age 59
Tenure 6 years
Phone469 862 3030
Webhttps://www.fusemedical.com
Reeg led the design, development, and successful commercialization of a spinal implant that received the approval of the FDA in 2013 and is currently manufactured and distributed by Fuse. Prior to forming Maxim, Mr. Reeg founded LMI Ortho, a distributor of spine and Orthopedic Implants purchased from domestic and international manufacturers and suppliers. While at LMI Ortho, Mr. Reeg acquired importation rights for a total joint orthopedic portfolio. Working with surgeons in the United States, Mr. Reeg expanded implant product lines and developed effective growth strategies based on design and market intelligence. Before entering the orthopedic industry with LMI Ortho in 1996, Mr. Reeg formed Spectramed, Inc., a multistate home respiratory company where he served as its President until the sale of Spectramed, Inc., to a national healthcare company in 2001

Fuse Medical Management Efficiency

The company has return on total asset (ROA) of (0.0331) % which means that it has lost $0.0331 on every $100 spent on assets. This is way below average. Fuse Medical's management efficiency ratios could be used to measure how well Fuse Medical manages its routine affairs as well as how well it operates its assets and liabilities.
Fuse Medical currently holds 200 K in liabilities with Debt to Equity (D/E) ratio of 106.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Fuse Medical has a current ratio of 1.13, suggesting that it is not liquid enough and may have problems paying out its financial obligations when due. Debt can assist Fuse Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Fuse Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fuse Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fuse to invest in growth at high rates of return. When we think about Fuse Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CEO Age

William GreenmanCerus
57
James MBAAethlon Medical
67
Timothy GoodnowSenseonics Holdings
62
Fuse Medical, Inc. manufactures and distributes medical device implants in the United States. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical operates under Medical Devices classification in the United States and is traded on OTC Exchange. Fuse Medical [FZMD] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Asset-0.0331

Fuse Medical Management Team

Elected by the shareholders, the Fuse Medical's board of directors comprises two types of representatives: Fuse Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fuse. The board's role is to monitor Fuse Medical's management team and ensure that shareholders' interests are well served. Fuse Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fuse Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Reeg, CEO, Director
Lawrence Yellin, Treasurer CFO
Mark Brooks, Chairman of the Board

Fuse Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fuse Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.0331
Profit Margin(0.04) %
Operating Margin(0.05) %
Current Valuation12.09 M
Shares Outstanding72.9 M
Shares Owned By Insiders88.44 %
Price To Sales0.57 X
Revenue20.41 M
Gross Profit11.94 M
EBITDA(1.42 M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Other Information on Investing in Fuse Pink Sheet

Fuse Medical financial ratios help investors to determine whether Fuse Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fuse with respect to the benefits of owning Fuse Medical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY